Orbis Research Presents The Global Neurodegenerative Disease Market accounted for USD XX billion in 2017 and is expected to reach USD XX billion by 2022, growing at a CAGR of XX% during the forecast period.
Neurodegenerative disorders can be genetic, however, their exact cause is unknown. They can arise due to the inability of mitochondria to function properly or because of the deposition of toxic proteins in the brain. The term neurodegenerative involves a few diseases under its broad definition and the patients often show symptoms that are interrelated to other diseases under the same broad term. The current market has no curative therapies and thus, available medications can only provide symptomatic relief.
Drivers and Restraints
The prevalence of neurological disorders has been increasing at a constant pace. The increasing awareness among the people about mental disorders and continuous R&D from major market players to find new and effective therapies for treating such disorders are the major market drivers during the period of the forecast. New types of drugs are expected to be launched in the next few years. The existing drugs are to face patent expiries and thus, new players can enter the market.
The market, however, is set to face obstacles due to the complexity of the disorders as well as the fact that the cause of these disorders is unknown most of the times, resulting in poor results for R&D activities. The currently available medications for such diseases and disorders are only successful in providing symptomatic relief. The market, hence, has a high potential for growth and should be tapped at the earliest.
Get a PDF Sample of Global Neurodegenerative Disease Market Research Report @:http://www.orbisresearch.com/contacts/request-sample/220476
Global Neurodegenerative Disease Market Segmentation
The global neurodegenerative disease market is segmented by the type of indication into Parkinsonâ€™s Disease, Amyotrophic Lateral Sclerosis, Alzheimerâ€™s Disease, and Huntington Disease. Out of these, Alzheimerâ€™s disease is the most prevalent, followed by Parkinsonâ€™s disease. The drugs used to provide symptomatic relief are broadly classified into N-methyl-D-aspartate receptor antagonists, selective serotonin reuptake inhibitor, and dopamine inhibitors.
Geographically, the market has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Asia-Pacific is expected to record the highest growth due to its large population base.
Some of the largest players in the market are:
TEVA Pharmaceuticals Industries
Place Purchase Order for this Report @:http://www.orbisresearch.com/contact/purchase/220476
Market analysis for the neurodegenerative disease market, with region-specific assessments and competition analysis.
Market definition along with the identification of key drivers, restraints, opportunities, and challenges.
Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with company profiles of key players with the analysis of their current strategic interests and key financial information.
Identification and analysis of the macro and micro factors that affect the global neurodegenerative disease market.
Insights of the market in the regions that have the highest potential for growth and to also identify the markets that are still untapped.